Anthracyclines and taxanes – Cumulative toxicity
When choosing a chemotherapy regimen, consider the cumulative toxicity when an anthracycline and a taxane are used together.
Discuss with people the benefits and risks of adding a taxane to anthracycline-containing regimens. Topics to discuss include those in table 4 and: the benefits of reduced cardiac toxicity and reduced nausea; the risks of additional side-effects, including neuropathy, neutropenia and hypersensitivity; the different side effects and dosing frequencies of different docetaxel and paclitaxel regimens, and the additional clinic visits that may be needed; that absolute benefit is proportional to absolute risk of recurrence
How this guidance was developed
This recommendation was adapted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted to September 2017 and used wording ('Consider') indicative of a conditional recommendation (using GRADE methods) by the source guideline authors. The source recommendation was simplified by removing the detail regarding additional topics to be discussed with the patients and linking the recommendation to Table 4 from the NICE guideline, which includes this detail.
Anthracyclines and taxanes – Cumulative toxicity
When choosing a chemotherapy regimen, consider the cumulative toxicity when an anthracycline and a taxane are used together.
This recommendation was adapted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted to September 2017 and used wording ('Consider') indicative of a conditional recommendation (using GRADE methods) by the source guideline authors. The source recommendation was simplified by removing the detail regarding additional topics to be discussed with the patients and linking the recommendation to Table 4 from the NICE guideline, which includes this detail.